Texture-modified food and fluids in dementia and residential aged care facilities

This article was published in the following Dove Press journal:
Clinical Interventions in Aging
2 August 2017
Number of times this article has been viewed

Introduction: Dysphagia is common in people living with dementia and associated with increased risk of aspiration pneumonia, dehydration, malnutrition, and death. Treatment options are limited and the use of texture-modified food and fluids (TMF) is a widespread clinical practice. This review aimed to evaluate the evidence for TMF in dementia.

Methods: A literature search using terms “dysphagia,” “texture-modified food and fluids,” “dementia,” and “aged care” was performed by using three electronic databases from 1990 to March 2017. Studies were assessed for suitability, then reviewed with data extracted, and grouped by categories of outcome measures.

Results: A total of 3,722 publications were identified, and 22 studies met the inclusion criteria. Studies were heterogeneous in design and methodology. There were no publications examining dementia exclusively; however, many subjects with dementia were included in studies of residential aged care facilities. TMF reduced the risk of aspiration seen on videofluoroscopy but not clinical aspiration and pneumonia. TMF was associated with lower daily energy and fluid intake and variable adherence.

Conclusion: There is a lack of evidence for people living with dementia and in residential care facilities that TMF improves clinical outcomes such as aspiration pneumonia, nutrition, hydration, morbidity, and mortality. Adverse effects including poorer energy and fluid intake were identified.

Keywords: modified diet, dysphagia, aspiration, aged care, nursing homes, dehydration, nutrition

Plain language summary
Texture-modified food and fluids (TMF) are used by many people in residential aged care facilities and are likely to be widely used in people living with dementia. TMF reduces aspiration detected by imaging but has not been shown to have impact on clinical outcomes including aspiration pneumonia. TMF may have negative effects on nutrition and hydration.

Introduction
Dysphagia is a common problem in older people and occurs in one half or more of people in residential aged care facilities and those living with dementia.1,2 The mechanisms for dysphagia are multifactorial, and factors that influence swallowing are advancing age, apraxia, cognitive fluctuation, impulsivity, reduced physical mobility, poor dentition, and dependence for feeding and medications.2,3 Dysphagia is a major risk factor for poor outcomes including aspiration pneumonia, malnutrition, dehydration, reduced functional status, increased hospital length of stay, and hospital re-admissions.1,2,4,5

Management options for dysphagia are limited. Texture-modified food and fluids (TMF, Table S1) were first studied in people with stroke and non-progressive...
dysphagia but are now used commonly in dementia and residential aged care facilities. However, there is limited evidence that the use of TMF results in significant positive health outcomes in stroke. Moreover, poor acceptability and adherence to TMF may contribute to reduced quality of life, malnutrition, and dehydration.

A recent international expert meeting on oropharyngeal dysphagia in older people concluded that there is not enough good quality evidence to recommend the use of TMF for the reduction of aspiration pneumonia risk and that there is some evidence that it cannot increase dietary or fluid intake for elderly people with chronic dysphagia. There have been three earlier systematic reviews on TMF specifically in people with dementia. These identified only two relevant studies and provided mixed recommendations. Alagiakrishnan et al concluded that TMF may be helpful despite variable efficacy for the prevention of aspiration. Both Affoo et al and Hanson et al concluded that TMF might reduce aspiration but does not have any impact on long-term morbidity and mortality. Another review focused on people in residential care and concluded that best practice could not be established, although it was suggested that thickened fluids may be effective if prescribed by a speech pathologist and prepared properly. There is a proposed Cochrane Review of TMF in people with dementia.

Given the prevalence of dementia and its strong association with dysphagia, understanding the role of TMF for management is crucial for guiding decision-making by clinicians, patients, and their carers. This review aimed to identify and evaluate the evidence for the use of TMF in people with dementia and in residential care.

Methods
Search strategy
Relevant studies from 1990 to July 2016 were identified through a literature search of multiple electronic databases (PubMed, MEDLINE, and Cochrane Library) in May 2014, June 2015, July 2016, and March 2017 by VP. Search terms for “dysphagia” and “texture-modified food and fluids” were combined with the terms for “dementia” and “aged care” (Table S2). The reference lists of identified publications were hand-searched for additional studies.

Selection criteria
Clinical studies were included if they were written in English, TMF was used as the intervention, and the studies examined the effect of TMF on at least one clinically relevant outcome. There were no studies that exclusively focused on dementia. Study populations entirely consisting of patients with dysphagia secondary to stroke and non-progressive neurological conditions were excluded. Article titles and abstracts were reviewed for suitability with exclusion of duplicates, literature reviews, case studies, and commentaries. If suitability was unclear, the article was read in its entirety.

Data extraction
The following data were extracted from the included articles and reviewed: study design, description of study population, size of study, duration of study, nature of intervention, outcomes including benefits and adverse effects, and investigators’ conclusion. Data were summarized in tables grouped by categories of outcome measures and was too heterogeneous to be subjected to pooled numerical or statistical analyses.

Results
The database search identified 3,692 results and the reference lists identified a further 30 results, representing a total of 3,722 articles. Title and abstract review excluded 3,662 articles, leaving 60 articles for full-text review. Twenty-two published studies were identified that met the inclusion criteria (Figure 1).

Prevalence of TMF
There were two studies where prevalence for TMF was the main objective and three studies where this could be extrapolated (Table S3). The prevalence of TMF varied between 8% and 67% in people living in residential care facilities, and subjects receiving TMF were more likely to have dementia (43.0% vs 33.0%, P<0.02). Indications for TMF included choking, feeding dependency, esophageal disease, poor dentition, refusal to eat, and cognitive deficits.

Aspiration
There were six studies that included subjects with dementia that have examined primary outcomes relating to aspiration in TMF (Table 1). The proportion of subjects with dementia ranged from 2% to 84%. Subjects primarily came from residential care, but also included hospital inpatients and community-dwelling subjects.

Two studies investigated the relationship between modified fluids and aspiration as demonstrated on videofluoroscopic swallowing studies (VFSS) while a third study utilized a self-composed screening tool as its measure of aspiration. Logemann et al found that the risk of aspiration on VFSS was reduced on thin fluids with chin down
posture, mildly thick fluids, and extremely thick fluids and that the risk was significantly reduced as modified fluid became thicker (68% vs 64% vs 53%, \( P < 0.001 \)). It was noted that more than half of the subjects with dementia aspirated on all three interventions.\(^{12}\) Leder et al found that moderately and extremely thick fluids were equally effective for reducing aspiration.\(^{3}\) Rosler et al used a screening tool based on the assessment of an immediate speech pathologist to define aspiration and found that risk was reduced as patients transitioned from water to sliced apple to pureed apple.\(^{20}\)

Three studies investigated clinical outcomes of pneumonia, hospital admission, or death.\(^{13,21,22}\) Robbins et al found no difference in the incidence of pneumonia and death over 3 months for thin fluids with chin down posture and thickened fluids (hazard ratio 0.163 vs 0.205, 95% confidence interval 0.43–1.36).\(^{13}\) Taniguchi et al found that TMF was associated with the increased incidence of hospital admission and death over 1 year.\(^{21}\) Low et al reported the only study showing improved clinical outcomes with TMF; however, the control group were subjects who were non-adherent with TMF. There were significantly more hospital admissions and deaths due to aspiration in non-adherent patients. There was no difference in the number of lower respiratory tract infections.\(^{22}\)

### Nutrition

Ten studies reported nutritional outcomes associated with TMF (Table 2).\(^{13,17,18,23–29}\) Most were performed in the residential care setting with an unspecified proportion of patients with dementia. Two studies were performed in acute hospital inpatients in neurology and aged care wards.\(^{23,24}\)

Five studies compared daily energy and protein intake on normal diet versus TMF.\(^{18,23,25–27}\) Statistical significance was achieved in three studies where patients on TMF tended to have lower energy intake\(^{18,23,25}\) and lower protein intake\(^{23}\) than when they were on a normal diet.

Robbins et al reported that 1.5% of subjects on thin fluids with chin down posture and 2.3% of subjects on thickened fluids had weight loss over 3 months.\(^{13}\) Massoulard et al correlated the type of diet with baseline nutritional status and found no significant association although the subgroups were small.\(^{27}\)

Two studies investigated whether nutritional outcomes could be improved using novel approaches to TMF.\(^{17,28}\)
Table 1 Results of studies examining aspiration in subjects on TMF

<table>
<thead>
<tr>
<th>Study</th>
<th>Subjects</th>
<th>Number of subjects (subjects with dementia)</th>
<th>Study design</th>
<th>Interventions</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leder et al²</td>
<td>Hospital inpatients who aspirate on thin but not thickened fluids, 21–96 years (USA)</td>
<td>84 (2)</td>
<td>Non-blinded single-subject randomized trial</td>
<td>Moderately thick vs extremely thick fluids</td>
<td>Aspiration during VFSS or clinical aspiration over 24 hours: 0% vs 0% (no statistical analysis)</td>
</tr>
<tr>
<td>Logemann et al²</td>
<td>Residential care and hospital patients who aspirate on thin fluids on VFSS, &gt;50 years (USA)</td>
<td>711 (483)</td>
<td>Non-blinded single-subject randomized trial</td>
<td>Thin fluids vs posturing with chin down vs mildly thick vs extremely thick fluids</td>
<td>Aspiration during VFSS: 68% vs 64% vs 53% (P&lt;0.001)</td>
</tr>
<tr>
<td>Low et al²</td>
<td>Residential care patients and people at home who were recommended for modified diet or fluids after VFSS (New Zealand)</td>
<td>140 (11)</td>
<td>Retrospective cohort study with 18-month follow-up</td>
<td>Adherent vs non-adherent with dietary recommendation</td>
<td>Self-reported hospital admissions for LRTI or aspiration: 15% vs 22% (P&lt;0.001) LRTI per person: 1.13 vs 0.94 (NS) Deaths due to aspiration: 39.5% vs 86% (P&lt;0.05)</td>
</tr>
<tr>
<td>Robbins et al³</td>
<td>Residential care and hospital patients who aspirate on thin fluids and perform equally on all three interventions on VFSS, &gt;50 years (USA)</td>
<td>515 (361)</td>
<td>Non-blinded parallel randomized controlled trial with 3-month follow-up</td>
<td>1. Thin fluids with chin down posture vs thickened fluids 2. Mildly thick vs extremely thick fluids</td>
<td>Cumulative incidence of clinical or radiological pneumonia, hazard ratio: 1. 0.098 vs 0.116, 0.84 (95% CI 0.49–1.45) (NS) 2. 0.084 vs 0.150, 0.5 (95% CI 0.23–1.09) (NS) Pneumonia or death, hazard ratio: 1. 0.180 vs 0.183, 0.98 (95% CI 0.65–1.48) (NS) 2. 0.163 vs 0.205, 0.76 (95% CI 0.43–1.36) (NS) Adverse events: 51 vs 68 (NS)</td>
</tr>
<tr>
<td>Rosler et al⁰</td>
<td>Hospital acute geriatric inpatients (Germany)</td>
<td>191 (161)</td>
<td>Non-blinded single-subject non-randomized controlled trial</td>
<td>Water vs sliced apple vs pureed apple</td>
<td>Aspiration during self-composed screening tool administered by speech pathologist: 35.6% vs 15.1% vs 6.3% (no statistical analysis)</td>
</tr>
<tr>
<td>Taniguchi et al¹¹</td>
<td>Residential care patients, &gt;65 years (Japan)</td>
<td>9,528 (not reported)</td>
<td>Multicenter non-blinded prospective cohort study with 1-year follow-up</td>
<td>Normal vs minced vs pureed vs parenteral diet</td>
<td>Cumulative incidence of death or hospital admission, odds ratio: 1.00 vs 1.23 (95% CI 1.05–1.45) vs 1.82 (95% CI 1.48–2.24) vs 1.82 (95% CI 1.41–2.35)</td>
</tr>
</tbody>
</table>

Note: Clinical aspiration defined by increased cough, temperature, or signs and symptoms of an upper respiratory tract infection.

Abbreviations: VFSS, videofluoroscopic swallowing study; LRTI, lower respiratory tract infection; TMF, texture-modified food and fluids; CI, confidence interval; NS, nonsignificant.
<table>
<thead>
<tr>
<th>Study</th>
<th>Setting</th>
<th>Number of subjects (subjects with dementia)</th>
<th>Study design</th>
<th>Interventions</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bannerman and McDermott</td>
<td>Residential care (UK)</td>
<td>30 (12)</td>
<td>Cross-sectional observational study using PW method</td>
<td>Normal diet vs TMF</td>
<td>Energy, kcal/day: 1,569 vs 1,281 (P &lt; 0.024)</td>
</tr>
<tr>
<td>Dahl et al</td>
<td>Residential care (Canada)</td>
<td>75 (unreported)</td>
<td>Cross-sectional observational study of single group using PW method and snack record</td>
<td>Pureed diet only</td>
<td>Energy, kcal/day: 1,074 ± 202</td>
</tr>
<tr>
<td>Germain et al</td>
<td>Residential care (Canada)</td>
<td>17 (8)</td>
<td>Single-blinded single-subject randomized controlled trial with 12-week follow-up using PW method and snack record</td>
<td>Usual TMF vs reshaped modified TMF</td>
<td>Change in energy from baseline, kcal/day: 81 ± 169 vs 61 ± 408 (P &lt; 0.03)</td>
</tr>
<tr>
<td>Johnson et al</td>
<td>Hospital inpatients (USA)</td>
<td>51 (unreported)</td>
<td>Cross-sectional observational study using CMS method</td>
<td>Normal diet vs pureed diet</td>
<td>Energy, kcal/day: 1,380 ± 207 vs 1,291 ± 140 (NS)</td>
</tr>
<tr>
<td>Keller et al</td>
<td>Continuing care facility and residential care (Canada)</td>
<td>42 (28)</td>
<td>Single-blinded single-subject randomized controlled trial with 9-month follow-up using VRS method</td>
<td>Usual commercial bulk TMF vs mixed commercial bulk and “ready-to-use” TMF</td>
<td>Achievement of initial prescribed weight goal of gaining weight, maintaining weight, and losing weight: 20%, 97%, 33% (no statistical analysis)</td>
</tr>
<tr>
<td>Massoulard et al</td>
<td>Residential care (France)</td>
<td>27 (unreported)</td>
<td>Cross-sectional observational study using PW method</td>
<td>Normal diet vs minced diet</td>
<td>Energy, kcal/plate: 143.1 vs 142.7 (NS)</td>
</tr>
<tr>
<td>McCormick et al</td>
<td>Hospital inpatients (UK)</td>
<td>22 (unreported)</td>
<td>Single-subject randomized controlled trial with 12-week follow-up</td>
<td>Bedside-thickened fluids vs pre-thickened fluids</td>
<td>Energy, kcal/day: 267 ± 583 (P &lt; 0.0001)</td>
</tr>
<tr>
<td>Nowson et al</td>
<td>Hospital inpatients and residential care (Australia)</td>
<td>215 (unreported)</td>
<td>Cross-sectional observational study using VRS method</td>
<td>Normal diet vs soft or minced diet vs pureed diet</td>
<td>Energy, kcal/day: 1,123 ± 931 vs 907 (P &lt; 0.001 for normal vs soft or minced, and normal vs pureed)</td>
</tr>
<tr>
<td>Robbins et al</td>
<td>Hospital inpatients (USA)</td>
<td>515 (361)</td>
<td>Non-blinded parallel randomized controlled trial with 3-month follow-up</td>
<td>Thin fluids with chin down posture vs mildly thick or extremely thick fluids</td>
<td>Weight loss: 1.5% of patients vs 2.3% (no statistical analysis)</td>
</tr>
<tr>
<td>Wright et al</td>
<td>Hospital inpatients (UK)</td>
<td>55 (unreported)</td>
<td>Cross-sectional observational study using PW method and snack record</td>
<td>Normal diet vs TMF</td>
<td>Energy, kcal/day: 1,460.5 ± 926.0 (P &lt; 0.0001)</td>
</tr>
</tbody>
</table>

Notes: PW method, plate wastage method records weight of plates before and after meal with total eaten extrapolated from weight of leftover meal; VRS method, visual rating scale records the scale (none left, mouthful left, 25%, 50%, 75%, mouthful eaten, all left) of each menu item served; CMS method, consumption monitoring system method records the percentage (none, 25%, 50%, 75%, all) of each menu item consumed.

Abbreviations: TMF, texture-modified food and fluids; NS, nonsignificant.
Germain et al found improved energy and protein intake over 12 weeks in a small randomized controlled trial where TMF was reshaped to look more similar to their original appearance.²⁸ Keller et al mixed a similar product with usual commercial bulk TMF and found that most subjects were able to maintain their weight though there were no differences in energy and protein intake.¹⁷

Hydration

Three studies examined total daily fluid intake as a primary outcome in people on TMF²⁴,²⁵,³⁰ and one study reported data on dehydration as an adverse outcome¹³ (Table 3). These studies were in hospital inpatients and patients in residential care.

Bannerman and McDermott²⁵ noted that patients on TMF had lower total daily fluid intake than patients on a normal diet (1,196 vs 632 mL, P<0.002). Only 6.7% of patients on a modified diet met their daily fluid requirements compared with 33.3% of patients on a normal diet.³³ Vivanti et al studied 25 hospital inpatients on thickened fluids and found that none achieved their daily fluid requirements without enteral or parenteral fluid support.³⁰ McCormick et al did not find any significant difference in total daily fluid intake based on the method of preparation of thickened fluids.²⁴

Robbins et al reported that 2.3% of subjects on thin fluids with chin down posture and 5.9% of subjects on mildly and extremely thick fluids had dehydration as diagnosed by a primary care physician. Statistical analysis was only performed for a combined outcome of dehydration, urinary tract infection, and fever which was not significant (5% vs 9%, P=0.055).¹³

Adherence

Three studies have investigated adherence to TMF as the primary outcome³¹–³³ and two studies as the secondary outcome¹³,²² (Table S4). Figures for non-adherence range from 10% to 52%.

Shim et al found better adherence with hospital inpatients but not with age, type of food or fluid modification, symptoms of aspiration, or severity of dysphagia.³¹ Low et al reported that non-adherent patients were more likely to be younger, from home, and on thickened fluids rather than modified diet.²²

Rosenvinge and Starke found that non-adherence in inpatients was more likely when TMF was inappropriately prepared or the wrong texture was provided.³² A multidisciplinary approach led to an improvement in adherence to thickened fluids after 2 months from 48% to 64%.

Table 3 Results of studies examining total daily fluid intake in subjects on TMF

<table>
<thead>
<tr>
<th>Study</th>
<th>Setting</th>
<th>Number of subjects (subjects with dementia)</th>
<th>Study design</th>
<th>Interventions</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bannerman and McDermott²⁵</td>
<td>Residential care (UK)</td>
<td>30 (12)</td>
<td>Cross-sectional observational study using standard cup weights</td>
<td>Normal diet vs TMF</td>
<td>Total daily fluid intake: 1,196 vs 632 mL (P&lt;0.002)</td>
</tr>
<tr>
<td>McCormick et al²⁴</td>
<td>Hospital inpatients (UK)</td>
<td>22 (unreported)</td>
<td>Single-subject randomized controlled trial with 12-week follow-up using graduated measuring cups</td>
<td>Bedside-thickened fluids vs pre-thickened fluids</td>
<td>Total daily fluid intake: 785 vs 795 mL (NS)</td>
</tr>
<tr>
<td>Robbins et al¹³</td>
<td>Hospital inpatients and residential care (USA)</td>
<td>515 (361)</td>
<td>Non-blinded parallel randomized controlled trial with 3-month follow-up</td>
<td>Thin fluids with chin down posture vs mildly thick or extremely thick fluids</td>
<td>Dehydration: 2.3% vs 5.9% (no statistical analysis)</td>
</tr>
<tr>
<td>Vivanti et al³⁰</td>
<td>Hospital inpatients (Australia)</td>
<td>25 (unreported)</td>
<td>Cross-sectional observational study of single group using CMS method</td>
<td>Thickened fluids only</td>
<td>Total daily fluid intake: 1,371 mL</td>
</tr>
</tbody>
</table>

Note: CMS (consumption monitoring system) method records the percentage (none, 25%, 50%, 75%, all) of each menu item consumed.

Abbreviations: TMF, texture-modified food and fluids; NS, nonsignificant.
with variation in level of function and proportion of people with dementia.

The studies identified by this review suggest that in people with dementia, TMF will reduce the risk of aspiration as seen on VFSS but that more than half will aspirate regardless of intervention. On the contrary, TMF was not clearly demonstrated to reduce clinically significant episodes of aspiration and related pneumonia. The only randomized controlled trial that included a majority of subjects with dementia was unable to identify any beneficial clinical outcomes, with no difference in the incidence of pneumonia or death over 3 months. This is in keeping with a recent international expert meeting on oropharyngeal dysphagia in older people that was unable to recommend the use of TMF for the reduction of aspiration pneumonia risk. Another study found that non-adherence with TMF was associated with the increased incidence of hospital admissions and death, but non-adherent patients are likely to have a poorer prognosis anyway. There are no studies about the impact of TMF on the quality of life in people with dementia or residential care.

There are no studies that specifically investigate the nutritional outcomes in people living with dementia on TMF. A number of studies reported that people in residential care are unlikely to meet their recommended daily energy requirements regardless of the type of diet and those on TMF have a lower daily energy intake compared with patients on a normal diet. There are no studies that address malnutrition as a primary clinical outcome. The studies identified by this review suggest that patients in hospital and residential care on TMF do not maintain their daily fluid requirements, consistent with conclusions from the stroke literature. There were no studies that translate daily fluid intake to hydration status including using surrogate outcome measures such as thirst, biochemical markers, or the need for parenteral fluids.

Adherence to TMF is variable depending on the setting, but there is no clear correlation with the type of food or fluid modification, age, and severity of dysphagia. One study demonstrated that staff education and TMF availability may improve adherence in hospital inpatients, whereas another study attempted to improve the appearance of TMF in order to increase adherence.

This review has several limitations including the small number of English-only studies identified, the heterogeneity of studies, and many with methodological bias and flawed design. Most studies had very small sample sizes and relatively short follow-up time periods. The populations studied were heterogeneous, with no studies consisting of subjects with dementia exclusively. Although five randomized controlled trials were included, some of these were weakened by the lack of an adequate control group with authors arguing that it would be unethical to include a no-treatment group. Further ethical considerations were raised by the most robust randomized controlled trial that introduced a selection bias. Their sample consisted of patients who aspirated or did not aspirate on VFSS no matter which intervention was used. All were single blinded as the nature of the intervention precluded the ability to blind the direct care providers.

There are multiple gaps in the literature as described above which should be considered for future research. The current evidence is not strong enough to preclude unmodified food and fluid as a control group on ethical grounds in future randomized clinical trials. These should explore further the relationship between TMF in people with dementia and clinically relevant outcomes of malnutrition, dehydration, and morbidity and mortality. Given the progressive and incurable nature of dysphagia secondary to dementia, incorporation of quality of life measures is essential. Other important research focuses are enhancing TMF as a nutritional alternative to normal diet through enrichment and examining alternative strategies for managing aspiration risk in people with dementia such as comfort feeding with better oral care or usage of free water protocols.

TMF is used regularly in patients with dysphagia secondary to dementia despite a lack of data and evidence for their beneficial effect on clinical outcomes including aspiration, pneumonia, hydration, nutrition, morbidity, and mortality. Further research is urgently needed to guide clinical practice on the management of aspiration and the use of TMF in people living with dementia who have aspiration and dysphagia.

Acknowledgment
We acknowledge the support of the Ageing and Alzheimer’s Institute.

Disclosure
The authors report no conflicts of interest in this work.

References


### Supplementary materials

**Table S1** Comparison between the Australian clinical food and fluid texture scale, the National Dysphagia Diet (US) and the UK (adult) texture classification systems for individuals with dysphagia

<table>
<thead>
<tr>
<th>Food texture</th>
<th>Australia</th>
<th>USA</th>
<th>UK</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regular</td>
<td>Regular</td>
<td>Regular</td>
<td>Normal</td>
</tr>
<tr>
<td>Texture A – soft (1.5 cm)</td>
<td>Dysphagia advanced (2.5 cm)</td>
<td>Texture E (1.5 cm)</td>
<td></td>
</tr>
<tr>
<td>Texture B – minced and moist (0.5 cm)</td>
<td>Dysphagia mechanically altered (0.6 cm)</td>
<td>Texture D</td>
<td></td>
</tr>
<tr>
<td>Texture C – smooth pureed</td>
<td>Dysphagia puree</td>
<td>Texture C</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Fluid viscosity</th>
<th>Australia</th>
<th>USA</th>
<th>UK</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regular</td>
<td>Thin 1–50 cP</td>
<td>Thin fluid</td>
<td>Naturally thick fluid</td>
</tr>
<tr>
<td>Level 150 – mildly thick</td>
<td>Nectar 51–350 cP</td>
<td>Thicknessed fluid – stage 1</td>
<td></td>
</tr>
<tr>
<td>Level 400 – moderately thick</td>
<td>Honey 351–1,750 cP</td>
<td>Thickened fluid – stage 2</td>
<td></td>
</tr>
<tr>
<td>Level 900 – extremely thick</td>
<td>Spoon or pudding &gt;1,750 cP</td>
<td>Thickened fluid – stage 3</td>
<td></td>
</tr>
</tbody>
</table>

**Note:** Reproduced with permission from Dietitians Association of Australia, Speech Pathology Association of Australia Limited. Texture-modified foods and thickened fluids as used for individuals with dysphagia: Australian standardised labels and definitions. Nutr Diet 2007;64(S2):S53–S76.¹

**Table S2** Search terms used in Medline

1. dysphagia.mp. or Deglutition Disorders/
2. oropharyngeal dysphagia.mp.
3. Deglutition/ or deglutition.mp.
4. deglutition disorders.mp. not 1 [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
5. aspiration.mp.
6. swallowing.mp.
7. 1 or 2 or 3 or 4 or 5 or 6
8. aged.mp. or “Aged, 80 and over”/ or Aged/ or Health Services for the Aged/
9. elderly.mp.
10. geriatrics.mp. or Geriatrics/
11. gerontology.mp.
12. Geriatric Assessment/ 
13. 8 or 9 or 10 or 11 or 12
14. Inpatients/ or inpatient*.mp. or Hospitalization/ 
15. acute care.mp.
16. hospitalisation.mp.
17. hospital care.mp.
18. Patient Admission/ or admission*.mp.
19. 14 or 15 or 16 or 17 or 18
20. dementia.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
### Table S3 Results of studies that describe the prevalence of use of TMF in dementia and residential care facilities

<table>
<thead>
<tr>
<th>Study</th>
<th>Setting</th>
<th>Number of subjects (subjects with dementia)</th>
<th>Prevalence of use of TMF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Castellanos et al</td>
<td>252 nursing homes (USA)</td>
<td>25,470 (not reported)</td>
<td>8.3% thickened fluids (60.1% mildly, 33.1% moderately, 6.3% extremely thick)</td>
</tr>
<tr>
<td>Cormier et al</td>
<td>1 long-term care and rehabilitation facility (Canada)</td>
<td>424 (143)</td>
<td>25.9% pureed diet</td>
</tr>
<tr>
<td>Groher and McKaig</td>
<td>2 nursing homes (USA)</td>
<td>658 (112 in modified diet group)</td>
<td>31% modified diet</td>
</tr>
<tr>
<td>Keller et al</td>
<td>1 continuing care facility (Canada)</td>
<td>361 (not reported)</td>
<td>13% modified diet</td>
</tr>
<tr>
<td>Nowson et al</td>
<td>1 nursing home (Australia)</td>
<td>139 (60)</td>
<td>29% modified diet</td>
</tr>
<tr>
<td></td>
<td>1 hostel (Australia)</td>
<td>76 (not reported)</td>
<td>10% soft diet, 0% pureed diet</td>
</tr>
</tbody>
</table>

**Abbreviation:** TMF, texture-modified food and fluids.

### Table S4 Results of studies examining adherence as an outcome in subjects on TMF

<table>
<thead>
<tr>
<th>Study</th>
<th>Setting</th>
<th>Number of subjects (subjects with dementia)</th>
<th>Methods</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colodny</td>
<td>Residential care patients who are independent with feeding (USA)</td>
<td>63 (unreported)</td>
<td>Qualitative interview</td>
<td>Reasons for non-adherence:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Denial of dysphagia and minimizing condition (50%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Dissatisfaction with texture and taste (39.7%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Informed decision and calculated risk (22.2%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Rationalizing non-adherence (21.4%)</td>
</tr>
<tr>
<td>Low et al</td>
<td>Residential care patients and people at home who were recommended for modified food (59%) or fluids (93%) after VFSS (New Zealand)</td>
<td>140 (11)</td>
<td>Retrospective cohort study with 18-month follow-up</td>
<td>Non-adherence: 21%</td>
</tr>
<tr>
<td>Robbins et al</td>
<td>Hospital inpatients and residential care patients who aspirate on thin fluids and perform equally on all three interventions on VFSS (USA)</td>
<td>104 (104)</td>
<td>Non-blinded parallel randomized controlled trial with weekly measures of adherence over 3 months</td>
<td>Non-adherence: 43% for thin fluids with chin down posture vs 27% for mildly thick fluids vs 19% for extremely thick fluids</td>
</tr>
<tr>
<td>Rosenvinge and Starke</td>
<td>Hospital inpatients (UK)</td>
<td>31 before, 54 after (unreported)</td>
<td>Sequential observational study before and after 2-month targeted intervention</td>
<td>Non-adherence for thickened fluids: 52% before, 36% after (P&lt;0.05)</td>
</tr>
<tr>
<td>Shim et al</td>
<td>Hospital inpatients who were recommended for modified food or fluids after VFSS (South Korea)</td>
<td>62 (5)</td>
<td>Retrospective cohort study with outpatient follow-up and qualitative interview</td>
<td>Non-adherence for modified diet: 18% before, 21% after (NS)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Non-adherence: 10% in hospital, 43.5% in outpatient (P=0.001)</td>
</tr>
</tbody>
</table>

**Reasons for non-adherence:**
- Dissatisfaction with texture (40%)
- Dissatisfaction with taste (40%)
- Difficulty in preparation (20%)
- Difficulty in swallowing (20%)

**Abbreviations:** NS, non significant; TMF, texture-modified food and fluids; VFSS, video fluoroscopic swallowing studies.
References